
    
      The design will be a randomized, double-blind, comparative, placebo- and active-controlled
      nine-period crossover study in healthy male volunteers. Subjects will be randomized and will
      receive each of the 9 treatments which will be separated by a minimum of 48 hours.The first
      treatment arm will always be the intravenous remimazolam. Eligible subjects will then be
      randomized to treatment sequence prior to study drug administration in treatment period 2.
      Each subject will participate in the study for up to 51 days, from Screening until Follow-up.
    
  